In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.

Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.

Magazine

Tasectan and Xilaplus in the new German GPGN Guidelines

Getting into treatment guidelines is lengthy, especially for new products that need time to gather sufficient scientific and real-life evidence.

Read more
Tasectan MDR Approved

GREAT NEWS! Noventure is delighted to announce that our medical device Tasectan has just been granted a new CЄ Certificate under MDR Regulation. 

Read more
New publication on the mode of action of Mucoprotectants: gelatin tannate and xyloglucan show similar effectivity on preventing Cholera Toxin-Induced diarrhea in experimental studies1

The newer antidiarrheal agents include the mucoprotectants gelatin tannate and xyloglucan. Both were able to attenuate cholera toxin-induced intra-loop water secretion in an experimental study in rats. 

Read more

Let's meet in ...

2025, Apr 10

Europharm International Business Meeting 2025

2025, May 14

ESPGHAN 2025

2025, May 20

Vitafoods 2025

2025, Jun 02

euroPLX 88

2025, Oct 28

CPHI 2025